The Prognostic Value of the Systemic Immune-Inflammation Index in Glioblastoma Patients and the Establishment of a Nomogram.

IF 2 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Medical Science Pub Date : 2025-04-16 DOI:10.1007/s11596-025-00047-x

Hao Xu, Li-Hao Jiang, Sheng-Nan Yu, Qing-Lan Ren

{"title":"The Prognostic Value of the Systemic Immune-Inflammation Index in Glioblastoma Patients and the Establishment of a Nomogram.","authors":"Hao Xu, Li-Hao Jiang, Sheng-Nan Yu, Qing-Lan Ren","doi":"10.1007/s11596-025-00047-x","DOIUrl":null,"url":null,"abstract":"Objective: The systemic immune-inflammation index (SII) has recently attracted significant interest as a new biomarker for predicting the prognosis of patients with glioblastoma (GBM). However, the predictive significance of it is still a subject of debate. This study intended to assess the clinical effectiveness of the SII in GBM and establish a nomogram.Methods: Receiver operating characteristic (ROC) curves were utilized to determine the optimal cut-off values of the SII. Kaplan-Meier (KM) survival curves were used to analyze the median overall survival (OS). Cox regression analysis was carried out to evaluate the associations between OS and different clinical factors. Based on the SII and clinical characteristics, a nomogram was constructed, and its value in clinical application was evaluated by means of decision curve analysis.Results: The optimal SII cut-off value was 610.13. KM analysis revealed that GBM patients with higher SII values had shorter OS (15.0 vs. 34.0 months, P = 0.044). Multivariate analysis demonstrated that a high SII was an independent predictor of poor outcome in GBM (HR = 1.79, P = 0.029). The nomogram incorporating the preoperative SII showed good predictive accuracy for GBM patient prognosis (C-index = 0.691).Conclusions: The SII is an independent predictive indicator for GBM. Patients with elevated SII levels tend to have a poorer prognosis. A nomogram combining the SII with clinical and molecular pathological features can assist clinicians in assessing the risk of death in GBM patients, providing a basis for individualized treatment decisions.","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11596-025-00047-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The systemic immune-inflammation index (SII) has recently attracted significant interest as a new biomarker for predicting the prognosis of patients with glioblastoma (GBM). However, the predictive significance of it is still a subject of debate. This study intended to assess the clinical effectiveness of the SII in GBM and establish a nomogram.

Methods: Receiver operating characteristic (ROC) curves were utilized to determine the optimal cut-off values of the SII. Kaplan-Meier (KM) survival curves were used to analyze the median overall survival (OS). Cox regression analysis was carried out to evaluate the associations between OS and different clinical factors. Based on the SII and clinical characteristics, a nomogram was constructed, and its value in clinical application was evaluated by means of decision curve analysis.

Results: The optimal SII cut-off value was 610.13. KM analysis revealed that GBM patients with higher SII values had shorter OS (15.0 vs. 34.0 months, P = 0.044). Multivariate analysis demonstrated that a high SII was an independent predictor of poor outcome in GBM (HR = 1.79, P = 0.029). The nomogram incorporating the preoperative SII showed good predictive accuracy for GBM patient prognosis (C-index = 0.691).

Conclusions: The SII is an independent predictive indicator for GBM. Patients with elevated SII levels tend to have a poorer prognosis. A nomogram combining the SII with clinical and molecular pathological features can assist clinicians in assessing the risk of death in GBM patients, providing a basis for individualized treatment decisions.

查看原文本刊更多论文

胶质母细胞瘤患者全身免疫炎症指数的预后价值及影像学的建立。

目的：系统性免疫炎症指数（SII）作为预测胶质母细胞瘤（GBM）患者预后的一种新的生物标志物，最近引起了人们的极大兴趣。然而，它的预测意义仍然是一个有争议的话题。本研究旨在评估SII在GBM中的临床疗效，并建立一个nomogram。方法：采用受试者工作特征（ROC）曲线确定SII的最佳临界值。Kaplan-Meier （KM）生存曲线分析中位总生存期（OS）。采用Cox回归分析评价OS与不同临床因素的相关性。根据SII和临床特征构建nomogram，通过决策曲线分析评价其临床应用价值。结果：最佳SII临界值为610.13。KM分析显示，SII值较高的GBM患者的OS较短（15.0个月比34.0个月，P = 0.044）。多因素分析表明，高SII是GBM预后不良的独立预测因子（HR = 1.79, P = 0.029）。结合术前SII的nomogram对GBM患者预后的预测准确性较好（C-index = 0.691）。结论：SII是GBM的独立预测指标。SII水平升高的患者往往预后较差。将SII与临床和分子病理特征相结合的nomogram，可以帮助临床医生评估GBM患者的死亡风险，为个性化治疗决策提供依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Medical Science Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

4.70

自引率

0.00%

发文量

126

期刊介绍： Current Medical Science provides a forum for peer-reviewed papers in the medical sciences, to promote academic exchange between Chinese researchers and doctors and their foreign counterparts. The journal covers the subjects of biomedicine such as physiology, biochemistry, molecular biology, pharmacology, pathology and pathophysiology, etc., and clinical research, such as surgery, internal medicine, obstetrics and gynecology, pediatrics and otorhinolaryngology etc. The articles appearing in Current Medical Science are mainly in English, with a very small number of its papers in German, to pay tribute to its German founder. This journal is the only medical periodical in Western languages sponsored by an educational institution located in the central part of China.